Months after reorg, Adaptimmune merges with fellow cell therapy developer
Adaptimmune is merging with TCR² Therapeutics in a bid to create a T cell therapy developer aimed at solid tumors.
The all-stock deal brings together both companies’ lead candidates — Adaptimmune’s afami-cel, which targets MAGE-A4, and TCR²’s mesothelin-targeting gavo-cel — as well as a pipeline of candidates engineered with T cell receptors, or TCRs. Unlike CAR-T therapies, TCR-T is not limited to surface antigens but can target antigens inside cancer cells.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.